Current Status of Computer-Aided Drug Design for Type 2 Diabetes

被引:31
作者
Bibi, Shabana [1 ]
Sakata, Katsumi [1 ]
机构
[1] Maebashi Inst Technol, Grad Sch Engn, Dept Environm & Life Engn, Maebashi, Gunma 3710816, Japan
关键词
Computer-aided drug design; diabetes mellitus; FDA-approved therapeutic options; glucose level; hypoglycemia; therapeutic mechanism-based drug design; PHOSPHATASE 1B INHIBITORS; BIOMOLECULAR SIMULATION; MOLECULAR DOCKING; ACCURATE DOCKING; PHARMACOPHORE; DISCOVERY; LIGAND; OBESITY; REDUCTASE; SOFTWARE;
D O I
10.2174/1573409912666160426120709
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background: Diabetes is a metabolic disorder that requires multiple therapeutic approaches. The pancreas loses its functionality to properly produce the insulin hormone in patients with diabetes mellitus. In 2012, more than one million people worldwide died as a result of diabetes, which was the eighth leading cause of death. Objective: Most drugs currently available and approved by the U.S. Food and Drug Administration cannot reach an adequate level of glycemic control in diabetic patients, and have many side effects; thus, new classes of compounds are required. Efforts based on computer-aided drug design (CADD) can mine a large number of databases to produce new and potent hits and minimize the requirement of time and dollars for new discoveries. Methods: Pharmaceutical sciences have made progress with advances in drug design concepts. Virtual screening of large databases is most compatible with different computational methods such as molecular docking, pharmacophore, quantitative structure-activity relationship, and molecular dynamic simulation. Contribution of these methods in selection of antidiabetic compounds has been discussed. Results: The Computer-Aided Drug Design (CADD) approach has contributed to successful discovery of novel antidiabetic agents. This mini-review focuses on CADD approach on currently approved drugs and new therapeutic agents-in-development that may achieve suitable glucose levels and decrease the risk of hypoglycemia, which is a major obstacle to glucose control and a special concern for therapies that increase insulin levels. Conclusion: Drug design and development for type 2 diabetes have been actively studied. However, a large number of antidiabetic drugs are still in early stages of development. The conventional target- and structure-based approaches can be regarded as part of the efforts toward therapeutic mechanism-based drug design for treatment of type 2 diabetes. It is expected that further improvement in CADD approach will enhance the new discoveries.
引用
收藏
页码:167 / 177
页数:11
相关论文
共 52 条
[11]   Application and limitations of X-ray crystallographic data in structure-based ligand and drug design [J].
Davis, AM ;
Teague, SJ ;
Kleywegt, GJ .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2003, 42 (24) :2718-2736
[12]   PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results [J].
Dixon, Steven L. ;
Smondyrev, Alexander M. ;
Knoll, Eric H. ;
Rao, Shashidhar N. ;
Shaw, David E. ;
Friesner, Richard A. .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2006, 20 (10-11) :647-671
[13]   Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B [J].
Doman, TN ;
McGovern, SL ;
Witherbee, BJ ;
Kasten, TP ;
Kurumbail, R ;
Stallings, WC ;
Connolly, DT ;
Shoichet, BK .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (11) :2213-2221
[14]   Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy [J].
Friesner, RA ;
Banks, JL ;
Murphy, RB ;
Halgren, TA ;
Klicic, JJ ;
Mainz, DT ;
Repasky, MP ;
Knoll, EH ;
Shelley, M ;
Perry, JK ;
Shaw, DE ;
Francis, P ;
Shenkin, PS .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (07) :1739-1749
[15]  
Gandhi G. Rajiv, 2012, Asian Pacific Journal of Tropical Biomedicine, V2, P281, DOI 10.1016/S2221-1691(12)60023-9
[16]  
Green Brian D, 2006, Expert Opin Emerg Drugs, V11, P525, DOI 10.1517/14728214.11.3.525
[17]   Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening [J].
Halgren, TA ;
Murphy, RB ;
Friesner, RA ;
Beard, HS ;
Frye, LL ;
Pollard, WT ;
Banks, JL .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (07) :1750-1759
[18]   Computational Drug Repositioning: From Data to Therapeutics [J].
Hurle, M. R. ;
Yang, L. ;
Xie, Q. ;
Rajpal, D. K. ;
Sanseau, P. ;
Agarwal, P. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 (04) :335-341
[19]  
International Diabetes Federation, IDF Diabetes Atlas
[20]   Structure-based design and combinatorial chemistry yield low nanomolar inhibitors of cathepsin D [J].
Kick, EK ;
Roe, DC ;
Skillman, AG ;
Liu, GC ;
Ewing, TJA ;
Sun, YX ;
Kuntz, ID ;
Ellman, JA .
CHEMISTRY & BIOLOGY, 1997, 4 (04) :297-307